Clinical trial

Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.

NCT01928576

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-11-06

PhasePHASE2

Study timeline

Study start (actual)2013-11-06Date precision: day

Registry last updated2024-05-03

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-Small Cell Lung Cancerunresolved

Epigenetic Therapyunresolved

Interventions

AzacitidineDRUG · verified · RxNorm: azacitidine

NivolumabDRUG · verified · RxNorm: nivolumab

Sponsors & collaborators

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkinslead sponsor

Rising Tide Foundationcollaborator

Stand Up To Cancercollaborator

Bristol-Myers Squibbcollaborator

Celgenecollaborator

Syndax Pharmaceuticalscollaborator

Rhone-Poulenc Rorercollaborator

Mapped research locations

BaltimoreMaryland, United States2 Los AngelesCalifornia, United States1 PittsburghPennsylvania, United States1 Washington D.C.District of Columbia, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01928576 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.